We’re pleased to share a new interview with Dr Ruizhi Wang, CEO of Abselion, conducted by The Medicine Maker’s editorial team.
In this conversation, Ruizhi reflects on how engineering principles can help make sense of biological complexity and why thoughtful measurement is central to modern bioprocessing. The discussion spans the growing diversity of antibody formats, the analytical challenges emerging in viral-vector development, and the importance of generating data that scientists can trust and compare across stages.
The interview covers:
• bridging engineering and biology
• evolving needs in antibody and AAV titre measurement
• the role of meaningful, comparable data
• how good assay design supports confident decision-making
Read the full interview here.